URGN UROGEN PHARMA
Health Care · Russell 2000
Next earnings: not announced yet
What 12 analyst firms say about UROGEN PHARMA: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 12 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8072
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8050
Recent analyst activity · last 90 days
Our tracked history has 4 reports on URGN from 4 analyst firms in the last 90 days (12 firms in the past year).
Comparing each firm's latest target with its previous one: 2 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| D Boral Capital | Jason Kolbert | Buy | 31 Mar 2026 | 33.00 USD |
| Goldman Sachs | Paul K Choi | Hold | 30 Apr 2026 | 48.00 USD |
| Guggenheim | Michael Schmidt | Buy | 6 Aug 2026 | 58.00 USD |
| H.C. Wainwright | Raghuram Selvaraju | Buy | 19 Oct 2026 | 75.00 USD |
| Jefferies | Amin Makarem | Buy | 10 Sep 2026 | 56.00 USD |
| Ladenburg Thalmann | Kevin M Degeeter | Buy | 11 May 2026 | Conflicting reports · excluded |
| Oppenheimer | Leland Gershell | Buy | 28 Oct 2026 | — |
| Piper Sandler | Kelsey Goodwin | Buy | 5 Aug 2026 | 58.00 USD |
| TD Cowen | Tara Bancroft | Buy | 5 Aug 2026 | 60.00 USD |
| UBS | Unnamed analyst | Buy | 9 Jul 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | 39.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:55 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.